Larimar Therapeutics Inc (LRMR) Stock Price, Quote & News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 844 511 9056

Website: larimartx.com

Address:

Three Bala Plaza East, Suite 506, Bala Cynwyd, United States

Bullishontherize Oct. 4 at 6:59 PM

$LRMR

0 · Reply

RavaK Oct. 4 at 4:28 PM

$LRMR does anyone smell something brewing here on Monday?

0 · Reply

Dr_Jan_Itor Oct. 4 at 9:22 AM

$LRMR New to this stock, read a bit on X and gonna take a small position only on technicals on Monday. Anyone care to give the bull case? Pls, no snarky comments

0 · Reply

SweepCastApp Oct. 4 at 6:34 AM

$LRMR: Unusual Options Activity Alerted PUT flow observed 74x contracts at Strike price of $7.5 Exp on 10/17/2025 with Premium of $28K and showing BEARISH Sentiment

0 · Reply

Roetes Oct. 4 at 6:03 AM

$LRMR I got uses to these sell the news moves on small bio techs. If you have doubt, listen to call they did this week via their investor relations. It cannot make you not bullish here...

0 · Reply

madardy Oct. 3 at 10:31 PM

$LRMR 6

0 · Reply

Buss Oct. 3 at 8:03 PM

$LRMR 2 monster block trades go thru on the close...clearly big money wants to be long heading into Monday morning.

1 · Reply

kenny91655 Oct. 3 at 8:03 PM

$LRMR Almost back to pre news release.

0 · Reply

BenGang Oct. 3 at 8:01 PM

$LRMR $SNDL $PLG

0 · Reply

Bullishontherize Oct. 3 at 8:00 PM

$LRMR

0 · Reply

Larimar Therapeutics, Inc. - Special Call

Sep 29, 2025, 11:20 AM EDT - 5 days ago

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Sep 29, 2025, 7:00 AM EDT - 5 days ago

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Sep 28, 2025, 5:00 PM EDT - 6 days ago

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Aug 14, 2025, 7:00 AM EDT - 7 weeks ago

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:15 PM EDT - 2 months ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 29, 2025, 11:50 PM EDT - 2 months ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Jul 29, 2025, 4:01 PM EDT - 2 months ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Jul 8, 2025, 7:00 AM EDT - 3 months ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jun 23, 2025, 7:00 AM EDT - 3 months ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 20, 2025, 4:05 PM EDT - 3 months ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Apr 30, 2025, 7:00 AM EDT - 5 months ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 7 months ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Jan 23, 2025, 4:05 PM EST - 9 months ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Jan 3, 2025, 5:49 PM EST - 9 months ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Dec 17, 2024, 1:39 PM EST - 10 months ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 16, 2024, 12:17 PM EST - 10 months ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 7:00 AM EST - 10 months ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 16, 2024, 2:59 PM EDT - 1 year ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oct 6, 2024, 9:28 PM EDT - 1 year ago

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

May 31, 2024, 4:11 PM EDT - 1 year ago

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 30, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 14, 2024, 6:15 AM EST - 1 year ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 12, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 2, 2023, 6:02 AM EDT - 2 years ago

Larimar: Friedreich's Ataxia Drug With Significant Potential

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

May 15, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

Mar 28, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

Feb 7, 2023, 4:05 PM EST - 2 years ago

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

Nov 21, 2022, 4:05 PM EST - 3 years ago

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

Nov 10, 2022, 7:00 AM EST - 3 years ago

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Nov 7, 2022, 4:05 PM EST - 3 years ago

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Oct 19, 2022, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

Bullishontherize Oct. 4 at 6:59 PM

$LRMR

0 · Reply

RavaK Oct. 4 at 4:28 PM

$LRMR does anyone smell something brewing here on Monday?

0 · Reply

Dr_Jan_Itor Oct. 4 at 9:22 AM

$LRMR New to this stock, read a bit on X and gonna take a small position only on technicals on Monday. Anyone care to give the bull case? Pls, no snarky comments

0 · Reply

SweepCastApp Oct. 4 at 6:34 AM

$LRMR: Unusual Options Activity Alerted PUT flow observed 74x contracts at Strike price of $7.5 Exp on 10/17/2025 with Premium of $28K and showing BEARISH Sentiment

0 · Reply

Roetes Oct. 4 at 6:03 AM

$LRMR I got uses to these sell the news moves on small bio techs. If you have doubt, listen to call they did this week via their investor relations. It cannot make you not bullish here...

0 · Reply

madardy Oct. 3 at 10:31 PM

$LRMR 6

0 · Reply

Buss Oct. 3 at 8:03 PM

$LRMR 2 monster block trades go thru on the close...clearly big money wants to be long heading into Monday morning.

1 · Reply

kenny91655 Oct. 3 at 8:03 PM

$LRMR Almost back to pre news release.

0 · Reply

BenGang Oct. 3 at 8:01 PM

$LRMR $SNDL $PLG

0 · Reply

Bullishontherize Oct. 3 at 8:00 PM

$LRMR

0 · Reply

RavaK Oct. 3 at 7:14 PM

$LRMR between yesterday and today almost 100M of trading volume - absolutely crazy for a small biotech like this

0 · Reply

RavaK Oct. 3 at 7:13 PM

$LRMR this has just got to be someone who knows something mega - no way someone buys this much on a Friday - great to see!!! We’ll be above $5.00 by next Friday

0 · Reply

hbkstockislife Oct. 3 at 7:06 PM

$LRMR At this rate 15$ by next month

0 · Reply

rangerhawkeye Oct. 3 at 6:54 PM

$LRMR shoulda bought the other day in 3’s

0 · Reply

Primitivetablemaker Oct. 3 at 6:30 PM

$LRMR load up because its going higher than 5.

0 · Reply

Primitivetablemaker Oct. 3 at 6:29 PM

$LRMR what did i say?

0 · Reply

RavaK Oct. 3 at 4:20 PM

$LRMR this stock is screaming buyout in the next 30 days Why else would there be millions in stock purchases AFTER the most recent data/ press release

2 · Reply